BioMarin Pharma (BMRN) Income Statement

Click line-items for a historical chart and %

Net product revenues	278.26M
Collaborative agreement revenues	1K
Royalty and license revenues	1.63M
Total revenues	279.9M
Cost of sales (excludes amortization of developed product technology)	50.74M
Research and development	160.83M
Selling, general and administrative	118.76M
Intangible asset amortization and contingent consideration	9.65M
Total operating expenses	339.98M
INCOME FROM OPERATIONS	-60.09M
Equity in the loss of BioMarin/Genzyme LLC	-104K
Interest income	1.63M
Interest expense	-9.98M
Net gain from sale of investments
INCOME BEFORE INCOME TAXES
Provision for income taxes	-24.02M
NET INCOME (LOSS)	-42.8M
NET INCOME (LOSS) PER SHARE, BASIC	-0.26
NET INCOME (LOSS) PER SHARE, DILUTED	-0.26
Weighted average common shares outstanding, basic	167.71M
Weighted average common shares outstanding, diluted	167.71M

Entities mentioned with BMRN

View All Entities